A Macromolecular Treatment for Ischemic Stroke

描述(由申请人提供)：在美国，中风约占每14例死亡中的1例，成为第三大死因。它也是导致残疾的头号原因，目前有300多万人因中风导致的脑损伤而遭受永久性的身体和精神损伤。BioPhyZica已经开发出一种名为HES-Z+VitC的治疗方法，用于治疗缺血性中风引起的毛细血管渗漏、浮肿和再灌注损伤。HES-Z+VitC由特定相对分子质量范围内的羟乙基淀粉(HES)分子溶液和抗氧化剂抗坏血酸(以下简称HES-Z+VitC)组成。羟乙基淀粉成分提供了封闭中风后形成的毛细血管内皮细胞间隙(毛孔)的生物物理作用，而抗氧化剂通过减少再灌注损伤提高了整体疗效。这项第一阶段STTR研究的目标是在动物模型中证明HES-Z+VitC可以减少缺血性中风后的神经功能缺陷。

DESCRIPTION (provided by applicant): Stroke accounts for about 1 of every 14 deaths in the United States making it the third leading cause of death. It is also the number one cause of disability, with more than 3 million people currently living with permanent physical and mental impairment from brain damage caused by stroke. BioPhyZica has developed a treatment, known as HES-Z + VitC, for treating capillary leak, edema, and reperfusion injury caused by ischemic stroke. HES-Z + VitC consists of a solution of hydroxyethyl starch (HES) molecules in a specific molecular weight range in combination with an antioxidant additive, ascorbic acid, hereafter referred to as HES-Z + VitC. The hydroxyethyl starch component provides a biophysical action of sealing at capillary endothelial gaps (pores) that develop after stroke, while the antioxidant enhances the overall efficacy by reducing reperfusion injury. The goal of this Phase I STTR research is to demonstrate, in an animal model, that HES-Z + VitC can reduce the neurological deficit after ischemic stroke.